COVID‐19 and the heart: An update for clinicians

Clinical Cardiology - Tập 43 Số 11 - Trang 1216-1222 - 2020
Ahmed Goha1,2, Kenechukwu Mezue3,2, Paul Edwards2, Felix Nunura2, Dainia Baugh2, Ernest C. Madu2
1Aga Khan University Hospital, Nairobi, Kenya
2Heart Institute of the Caribbean and HIC Heart Hospital, Kingston, Jamaica
3Department of Hospital Medicine, Altru Health System, Grand Forks, North Dakota, USA

Tóm tắt

AbstractSARS‐CoV‐2, the cause of the COVID‐19 pandemic has significantly impacted cardiovascular healthcare. Patients with pre‐existing cardiovascular disease are at higher risk of morbidity and mortality. The virus may affect the heart directly and indirectly with clinical syndromes of acute myocardial injury, myocarditis, acute coronary syndromes, heart failure, arrhythmias, and venous thromboembolism. Some therapeutics under investigation for COVID‐19 may also have adverse cardiac effects. The involvement of the RAAS system in viral entry makes it pertinent to consider the effects of medications that modulate the system. Comprehensive knowledge of peculiar cardiovascular manifestations of COVID‐19 and the role of RAAS in the prognosis of COVID‐19 disease is needed for optimal patient management.

Từ khóa


Tài liệu tham khảo

World Health Organization (WHO). Coronavirus disease (COVID‐19) Situation report 124.https://www.who.int/docs/default‐source/coronaviruse/situation‐reports/20200523‐covid‐19‐sitrep‐124.pdf?sfvrsn=9626d639_2

10.1016/S0140-6736(20)30566-3

10.1056/NEJMoa2002032

10.1001/jamacardio.2016.0433

Harris JE, 2019, Frequency of troponin elevations in patients with influenza infection during the 2017–2018 influenza season, Int J Cardiol Hear Vasc, 22, 145

10.1093/eurheartj/ehaa231

10.1001/jama.2020.6775

10.1001/jama.2020.6887

10.15585/mmwr.mm6912e2

10.1016/S0140-6736(20)31103-X

10.15585/mmwr.mm6915e3

JPHMPDirect. Identifying differences in COVID‐19 rates on American Indian reservations.https://jphmpdirect.com/2020/04/28/identifying-differences-in-covid-19-rates-on-american-indian-reservations/

10.1161/CIRCRESAHA.120.317055

10.1016/j.ijcard.2020.03.063

10.1016/j.dsx.2020.03.013

10.1001/jama.2020.3204

10.1038/s41379-020-0536-x

10.1016/S2665-9913(20)30121-1

ESC. ESC Guidance for the Diagnosis and Management of CV Disease during the COVID‐19 Pandemic.2020.https://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-Guidance#p04

10.1111/jth.14859

10.1016/j.hrthm.2020.05.001

10.1016/S0140-6736(20)30183-5

10.1126/science.abb3221

10.1161/CIRCULATIONAHA.120.046941

10.1161/CIRCOUTCOMES.120.006631

10.1002/phar.2398

10.1177/1747493020921664

10.1136/jnnp-2020-323586

10.1001/jamanetworkopen.2020.8857

Mehra MR, 2020, Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID‐19: a multinational registry analysis, Lancet

10.1016/S0140-6736(20)31022-9

10.1073/pnas.2004168117

10.1002/path.2987

10.1016/j.cell.2020.02.052

10.1161/CIRCULATIONAHA.104.510461

Junyi G, 2020, Coronavirus disease 2019 (COVID‐19) and cardiovascular disease: a viewpoint on the potential influence of angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 Infection, J Am Heart Assoc, 9, e016219, 10.1161/JAHA.120.016219

10.5114/aoms.2020.94655

10.1159/000375362

10.1177/135965350601100803

European Medicines Agency. EMA gives advice on the use of non‐steroidal anti‐inflammatories for COVID‐19.https://www.ema.europa.eu/en/news/ema-gives-advice-use-non-steroidal-anti-inflammatories-covid-19

Thông tin
Thông tin xuất bản

Clinical Cardiology

Tập 43 Số 11

1216-1222

Thông tin tác giả